Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
Hideki Furuya, Toru Sakatani, Sunao Tanaka...
https://pubmed.ncbi.nlm.nih.gov/38167321/Actively Recruiting
Led by Cedars-Sinai Medical Center · Updated on 2026-02-04
300
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are evaluating a new urine test called a multiplex ELISA assay to improve the detection of recurrent bladder cancer in patients with a history of this disease. Current urine tests like voided urinary cytology miss about half of early-stage or low-grade bladder cancers, which are most treatable. This study aims to validate the new test by comparing its results to cystoscopy, an invasive procedure used to monitor bladder cancer recurrence. This observational study involves collecting voided urine samples from patients with a history of non-muscle invasive or muscle invasive bladder cancer treated with bladder-sparing methods or not yet treated, diagnosed within the past 24 months. Participants may be undergoing regular surveillance every 3 to 12 months depending on their risk level. The multiplex ELISA assay results will be compared to those from cystoscopy and other urine tests like voided urinary cytology and NMP22 BladderCheck over a period of two years. Participants will provide informed consent and follow their scheduled surveillance visits for up to two years. Researchers will monitor the sensitivity and specificity of the multiplex ELISA assay by comparing it to cystoscopy results, which involve inserting a camera to inspect the bladder. The study will also compare how well the new test performs against existing urine tests. This non-invasive approach could reduce the need for frequent cystoscopies if shown to be reliable.
CONDITIONS
A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer
C
Charles Rosser, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Cedars-Sinai Medical Center
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 years
Participants undergo regular surveillance visits to monitor their bladder cancer history using the multiplex ELISA assay and cystoscopy.
Visits every 3 months for high/intermediate risk participants or every 6 to 12 months for low risk participants
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Hideki Furuya, Toru Sakatani, Sunao Tanaka...
https://pubmed.ncbi.nlm.nih.gov/38167321/Hideki Furuya, Toru Sakatani, Sunao Tanaka...
https://pubmed.ncbi.nlm.nih.gov/38045238/Cedars-Sinai Medical Center
Lead Sponsor
Fred Hutchinson Cancer Center
Collaborating Sponsor